Brieka

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brieka

Brieka is a prescription-only medicinal product containing a single active substance, Pregabalin, which is a synthetic derivative used to stabilize overactive nerve signaling. This foundational section defines the medicine by its composition, type, and general functional category.


What Type of Medicine is Brieka and What is its Composition?

Brieka is the brand name for the active ingredient Pregabalin, which is structurally similar to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). This product is broadly classified as both an Anticonvulsant and an Anxiolytic agent due to its stabilizing effects on the central nervous system.

Pregabalin belongs to the gabapentinoid pharmacological class, chemically defined as a GABA analogue. Gabapentinoids are clinically recognized for their ability to dampen excessive neuronal activity. The medicine is a single-entity drug, relying solely on Pregabalin for its efficacy. Brieka is formulated exclusively for oral use and is typically presented as hard capsules, though the active ingredient is also available in preparations such as oral solutions and extended-release tablets to suit different patient needs.


What is the General Function of a Gabapentinoid like Brieka?

The general function of Pregabalin is to act as a nerve-calming agent by reducing the excessive excitability of neurons in the central nervous system. Its mechanism involves binding to the alpha2delta subunit of voltage-gated calcium channels, a process which reduces the calcium-dependent release of various excitatory neurotransmitters. This modulation decreases nerve signal transmission.

By modulating this release and stabilizing overactive nerve pathways, Brieka provides the general benefit of nervous system stabilization. This action helps to reduce widespread hypersensitivity and the rapid transmission of impulses, supporting its utility across therapeutic categories that require the dampening of abnormal electrical signals.

Regulatory References

  1. EMA EPAR for Lyrica (Pregabalin)

What side effects are possible with Brieka?

Possible Side Effects and Safety Information

The safety profile of Brieka (Pregabalin) is organized by regulatory authorities according to the frequency and type of documented adverse reactions. These classifications help define the drug's overall risk profile based on clinical trial and post-marketing data.

Frequency-Classified Adverse Reactions

Adverse reactions most frequently reported are categorized as Very Common (ge 1/10) and include dizziness and somnolence (drowsiness). Common (ge 1/100 to < 1/10) effects often involve the nervous system (e.g., loss of coordination, memory impairment) and metabolic changes, such as weight gain and peripheral oedema (swelling of the hands and feet).

Serious Adverse Reactions (SARs)

Regulatory documents list certain rare but clinically significant safety concerns. These include the potential for severe respiratory depression, especially when used concurrently with other CNS depressants (like opioids), or in patients with underlying breathing difficulties. Other serious documented reactions are angioedema (life-threatening swelling of the face, mouth, or throat) and an increased risk of suicidal thoughts and behavior associated with anti-epileptic agents.

Population and Exposure Safety Notes

Official safety information addresses risks in specific patient groups. Since the medicine is eliminated primarily by the kidneys, patients with renal impairment require dose adjustment. Older adults may experience a greater incidence of dizziness and somnolence, which increases the risk of falls and accidental injury. Regarding duration of use, regulatory labels specify that abrupt or rapid cessation of therapy may lead to withdrawal symptoms and should be managed by a gradual withdrawal process.

Overdose and Emergency Response

Overdose and When to Seek Help

If you suspect an overdose of Brieka (pregabalin), seek emergency medical attention immediately, even if you do not feel sick. Take the medicine container or packaging with you to the emergency room to show the healthcare providers.

Overdoses up to 15 grams have been reported. The most commonly documented overdose presentations relate to the central nervous system and include:

  • Somnolence (extreme sleepiness)
  • Confusional state
  • Agitation or restlessness
  • Seizures (convulsions)
  • Loss of consciousness (coma)

Increased Risk of Severe Outcomes:

Symptoms may become more serious, including leading to coma and respiratory depression (slowed or shallow breathing), when the drug is taken in combination with alcohol or other CNS depressants (such as opioid pain medicines). Serious breathing problems are also a particular risk for elderly patients and those with pre-existing lung or breathing conditions.

Management of Overdose:

There is no specific antidote for Brieka overdose. Treatment is generally supportive, involving monitoring vital signs and providing necessary clinical support. Because the drug is primarily cleared by the kidneys, procedures like haemodialysis can effectively remove the drug from the bloodstream in cases of severe overdose or compromised kidney function.

Therapeutic Uses of Brieka

What Brieka Treats: Main Uses and Benefits

Brieka is relevant in clinical settings that involve acute or unstable symptom patterns. Its therapeutic application is established for several specific conditions requiring stabilization of nerve signaling.

The medicine is commonly used for managing the persistent and often severe symptoms related to physical discomfort, including chronic pain conditions like diabetic neuropathy and postherpetic neuralgia (pain after shingles). It is also applied in conditions presenting with systemic discomfort, such as fibromyalgia, and for managing the symptom clusters of Generalized Anxiety Disorder (GAD). It may also be used as an adjunctive treatment for partial-onset seizures (focal seizures) in adults and children.

The medicine offers symptomatic relief that helps patients cope more steadily with these difficult, persistent episodes. As one clinician describes the goal of therapy:

“It provides support that helps ease the overall symptom burden during periods of heightened discomfort.”

Applying this supportive symptom management may assist with maintaining functional stability and supports general well-being when symptoms become more noticeable.


Quick Fact: Relevant for Managing Chronic Neuropathic Symptoms and Widespread Anxiety


Regulatory References

  1. European Medicines Agency's overview of Lyrica (Pregabalin)

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility profile for Brieka (pregabalin) is defined by one absolute exclusion and several conditional restrictions based on a patient's physical state, as documented in official government regulatory information.

Contraindications

  • Hypersensitivity: The medicine is strictly contraindicated for individuals with a known allergy or hypersensitivity to the active substance (pregabalin) or any of the product's excipients.

Populations Requiring Restriction or Special Consideration

Population Group Eligibility Status Regulatory Requirement
Renal Impairment Restricted / Conditional Mandatory dose adjustment is required based on creatinine clearance, as the drug is mainly cleared by the kidneys.
Pregnancy Avoided / Restricted Use is not recommended unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. Women of child-bearing potential must use effective contraception.
Breastfeeding Not Recommended Breastfeeding is generally not advised as the drug is present in human milk.
Children/Adolescents Restricted / Not Established Use for non-seizure indications is generally restricted to adults (18+) as efficacy and safety have not been established in younger populations for those uses.
Elderly (Over 65) Use with Caution Use with caution due to the higher potential for decreased kidney function, which may necessitate a dose reduction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacokinetic Interaction Profile

The official regulatory profile indicates a minimal risk of pharmacokinetic interactions. The active substance, Pregabalin, is excreted largely unchanged in the urine, undergoing negligible metabolism (less than 2% of the dose) and neither inhibiting nor inducing major CYP enzymes. Consequently, it is classified as unlikely to produce, or be subject to, clinically significant pharmacokinetic drug interactions. This is confirmed by studies showing no clinically relevant interaction with antiepileptic drugs such as phenytoin, carbamazepine, or valproic acid.

Pharmacodynamic and Substance Interactions

Interactions are primarily pharmacodynamic (additive effects).

  • CNS Depressants: Co-administration with Central Nervous System (CNS) depressants, including opioids and ethanol (alcohol), results in additive effects that increase the risk of serious respiratory depression, heightened dizziness, and somnolence. Caution is advised due to these documented additive effects.
  • Thiazolidinedione Agents: Co-administration with thiazolidinedione antidiabetic agents is associated with an additive risk of peripheral edema (fluid retention).

Timing and Population Notes

The medicine may be administered with or without food, as food does not clinically alter the total extent of absorption. The regulatory label notes that the risk of severe respiratory depression from co-administration with CNS depressants is heightened in populations with compromised respiratory function or among the elderly.

Mechanism of Action

The mechanism of Pregabalin (Brieka) centers on its highly specific binding to the alpha-2-delta (alpha2delta) subunit of presynaptic Voltage-Gated Calcium Channels (VGCCs) in the central nervous system. This molecular interaction is a form of modulation that directly influences the channels' function. The binding reduces the necessary calcium ion ( Ca^2+) influx into the presynaptic nerve ending, which is the essential trigger for synaptic communication.

This limited calcium influx initiates the core pharmacological cascade: the indirect suppression of calcium-dependent release of key excitatory neurotransmitters, including Glutamate and Substance P, into the synaptic cleft. By decreasing the total quantity of these released mediators, Pregabalin alters the overall state of neuronal excitability. This action primarily affects neural circuits characterized by high-frequency firing, promoting the establishment of modulated signal dynamics within the nervous system, which defines the drug's physiological activity profile.

Dosage and Administration Information

Brieka is an orally administered prescription product available as Immediate-Release (IR) capsules, oral solution, and Extended-Release (ER) tablets. The instructions for use are determined by the specific formulation and the patient's physiological status.

Dosing and Schedule

The standard initial daily dosage for adults is mathbf150 mg, which is typically administered in two or three divided doses. The total daily dose is progressively increased (titrated) over an interval of one week or more, based on individual response, up to a maximum of mathbf600 mg/day.

Formulation Frequency & Timing Administration Condition
IR Capsules / Solution 2 to 3 divided doses per day May be taken with or without food.
ER Tablets Once daily Must be taken after the evening meal and swallowed whole (not to be crushed or chewed).

Procedural Rules and Adjustments

The administration of this product involves specific procedural steps for long-term use. If treatment is to be discontinued, the dosage is gradually reduced over a minimum period of one week. Dose adjustment is performed for individuals with reduced kidney function (renal impairment) because the medicine is primarily eliminated through renal excretion. The total daily dose is reduced based on the patient's creatinine clearance (CLcr). Older adults may also require a dosage reduction due to the likelihood of age-related decreased renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Brieka (Pregabalin)

The evidence landscape for Brieka includes findings from Randomized Controlled Trials (RCTs), which were submitted as part of the initial regulatory assessment. These studies, often comparing the medicine to a placebo, have been used to evaluate outcomes across the studied indications. The findings from these trials, combined with systematic reviews and meta-analyses, contribute to the evidence landscape concerning symptom patterns in specific patient populations.

Evidence for Use in Chronic Neuropathic Pain

Research for this indication was conducted using short-term RCTs, typically lasting 8 to 13 weeks, used in research exploring how symptoms change over time. These studies were applied in populations of adults diagnosed with specific forms of chronic pain, such as diabetic peripheral neuropathy and postherpetic neuralgia. Findings describe patterns observed where patients reported changes in pain scores over the short-term period, which were often greater than the changes reported by those receiving placebo. The research mainly addresses peripheral neuropathic pain and provides limited context for other forms.

Evidence for Use in Fibromyalgia and Generalized Anxiety Disorder (GAD)

For fibromyalgia, short-to-intermediate term RCTs explored various outcomes related to systemic or functional imbalance, specifically measuring changes in pain intensity, sleep disturbance, and scores related to fatigue. Findings describe patterns observed where patients reported changes in these measures. For GAD, short-term RCTs, supplemented by longer maintenance studies, examined changes in anxiety severity scores. Long-term studies monitored these responses over defined time intervals, providing some insight into the duration of the observed symptom patterns.

Evidence in Specific Populations and Uncertainties

The medicine was studied for use in pediatric populations (infants 1 month and older) for the specific indication of partial-onset seizures as an add-on therapy, but research only characterizes this adjunctive use. The research base mostly consists of adult populations for pain and anxiety indications. Key limitations include that follow-up durations were limited for characterizing long-term functional outcomes across most chronic conditions. Data for certain subgroups, such as patients with multiple co-occurring conditions, remain insufficient, indicating areas where further scientific inquiry is needed.

Key Studies & References

  1. Pregabalin for neuropathic pain in adults: A Cochrane systematic review and meta-analysis
  2. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder
  3. LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint (Study in patients 1 month to less than four years of age)

Frequently Asked Questions (FAQ)

Common questions about Brieka (FAQ)


Q: Is Brieka safe to take long-term?

A: Studies and official information indicate that Brieka is used for the management of chronic conditions, such as certain types of nerve pain and fibromyalgia. Its use in clinical practice is described for long-term management of certain chronic conditions. Because the medicine has a potential for dependence, prescribers are advised to monitor patients carefully, especially when adjusting the dose or ending treatment.


Q: Can I take Brieka with over-the-counter cold medicine?

A: Official product information warns that taking this medicine with other Central Nervous System (CNS) depressants may increase side effects like sleepiness, dizziness, and difficulty concentrating. Some over-the-counter cold medicines can contain ingredients that act as CNS depressants. Official information emphasizes the importance of informing the healthcare provider about all medicines and products being taken.


Q: Can Brieka affect my sleep?

A: According to official safety data, effects on sleep are commonly reported. This includes both somnolence, which is excessive drowsiness, and insomnia, which is difficulty falling or staying asleep. These are listed among the common adverse reactions in the regulatory documents.


Q: How long can I expect to be on Brieka treatment?

A: The required duration of treatment varies significantly based on the condition being addressed. Official guidelines state that for chronic nerve pain or anxiety, use may continue for several months. For long-term epilepsy control, it may be needed for many years. The necessary duration of use is a decision made by the prescribing healthcare professional.


Q: What is the difference between Brieka and a supplement?

A: Brieka is a prescription medication that contains the active substance Pregabalin. Unlike a supplement, it is regulated by governmental authorities and is federally classified as a controlled substance (Schedule V in the US) due to its potential for abuse and dependence. It is only available through a prescription.


Q: Are there any warnings about driving or operating machinery with Brieka?

A: Official patient information includes a warning that this medicine can cause dizziness and somnolence (drowsiness). These effects may impair a person's judgment, thinking, and motor skills. Regulatory warnings state that patients must be cautious regarding activities like driving or operating complex machinery until the medicine's effects are understood.


Q: What does 'contraindication' mean for Brieka?

A: A contraindication is a medical situation or condition where a drug must not be used because the risk outweighs any potential benefit. For Brieka, the main contraindication is a known allergy or hypersensitivity to the active substance, Pregabalin, or to any of the inactive ingredients found in the product.


Q: Are there any long-term research updates on Brieka?

A: Clinical studies initially provided evidence for the effectiveness of the drug in the short-term management of its approved conditions. Long-term safety and effects are continuously monitored through post-marketing surveillance programs, which collect data from patient use after the drug is made available to the public.


Q: Can I take herbal remedies while on Brieka?

A: The official product label advises that patients must inform their healthcare provider about all medicines, vitamins, and herbal products being taken. This is necessary because interactions can occur between the medicine and herbal remedies, potentially altering the drug's effect or increasing the risk of adverse reactions.


Q: What is the full list of ingredients in Brieka?

A: The active substance in Brieka is Pregabalin. The complete list of inactive ingredients, or excipients, is detailed in the full Prescribing Information for the product. This information is included because the medicine is strictly contraindicated if a patient has a known allergy to the active substance or any of these components.


Q: Is there a risk of dependency with Brieka?

A: Yes, regulatory bodies classify Brieka as a controlled substance due to its potential for abuse and physical dependence. This classification means there is a risk, and patients must be carefully monitored by their prescriber throughout treatment, especially when the dose is being changed or the drug is being stopped.


Q: How quickly does Brieka start to work?

A: Studies indicate that patients may begin to see an improvement in their condition, such as reduced pain, as early as the first week of treatment. However, it is important to note that the full therapeutic effect of the medicine may take up to a month to be achieved.


Q: What happens if I miss a day of taking Brieka?

A: Official patient instructions advise taking the missed dose as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular dosing schedule should be resumed. Regulatory guidelines state that a double dose should not be taken to compensate for a missed dose.


Q: Is Brieka available as a generic version?

A: The active ingredient in Brieka is Pregabalin. Since the patent exclusivity period has expired, generic versions are available and regulated under the active ingredient name in official drug documentation.


Q: Does taking Brieka require special blood tests?

A: Dosing must be adjusted for patients who have reduced kidney function, based on a measurement called creatinine clearance. Due to this requirement, routine laboratory monitoring may be necessary to ensure the dose is appropriate for the patient's kidney health.


Q: How do I know if Brieka is working for me?

A: Therapeutic success is determined by a healthcare provider through periodic assessments of the patient's underlying condition and the symptoms being treated. The evaluation focuses on assessing the benefit of the medicine against any potential adverse effects.


Q: Is Brieka considered a controlled substance?

A: Yes, Brieka is classified as a controlled substance by regulatory agencies in the United States and other countries. In the US, it is a Schedule V controlled substance due to its recognized potential for abuse and dependence.


Q: Does Brieka have a Black Box Warning?

A: The US Prescribing Information includes a prominent warning about the increased risk of suicidal thoughts or behavior associated with antiepileptic drugs (AEDs), a drug class to which Brieka belongs. The warning requires that patients be monitored for changes in behavior throughout the course of treatment.


Q: What should I do if a side effect seems serious?

A: Official patient information describes that signs of serious side effects, such as allergic reaction or difficulty breathing, are situations requiring immediate contact with a healthcare provider or seeking emergency medical care. Examples of severe reactions include swelling of the face, tongue, or throat.


Q: Does Brieka affect blood pressure?

A: Official safety data confirms that the medicine can affect blood pressure. Both high blood pressure (hypertension) and low blood pressure (hypotension) are listed among the uncommon adverse reactions in the drug's regulatory documents.


Q: How long does the effect of one dose of Brieka last?

A: According to official pharmacological data, the mean elimination half-life of the drug is approximately 6.3 hours. The half-life refers to the time it takes for half of the dose to be cleared from the body.


Q: Does Brieka cause any sexual side effects?

A: Official safety data lists various sexual side effects among the adverse reactions. These can include decreased libido (reduced sex drive), sexual dysfunction, delayed ejaculation, and erectile dysfunction.


Q: When was Brieka approved by the FDA?

A: The initial approval for the capsule formulation of the active ingredient (Pregabalin) by the US Food and Drug Administration (FDA) was granted in December 2004.

How should Brieka be stored and disposed of?

How to Store and Dispose of Brieka

Official regulatory documents define specific, mandatory conditions for storing Brieka (pregabalin) hard capsules to maintain stability and shelf life.


Official Storage Requirements

Condition Requirement
Maximum Temperature Store below 30 C.
Protection Must be protected from light and moisture.
Packaging Keep the medicine in its original container, such as the Aluminium/PVC blisters, to ensure protection.
Shelf Life Stability is established for 2 years (or 36 months, depending on the approved formulation) when stored as directed.

Disposal Instructions

Official regulatory labeling does not include specific, unique instructions for disposal beyond the standard requirement to handle the unused medicinal product or waste material in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brieka found in:

A-Z Index: